Cardiac calcium handling on trial: targeting the failing cardiomyocyte signalosome.
作者信息
Pleger Sven T, Raake Philip, Katus Hugo A, Most Patrick
机构信息
From the Molecular and Translational Cardiology, Department of Internal Medicine III (S.T.P., P.R., H.A.K., P.M.), DZHK (German Center for Cardiovascular Research), Partner site Heidelberg/Mannheim (H.A.K., P.M.), Heidelberg University Hospital, Heidelberg University, Heidelberg, Germany; and Center for Translational Medicine, Department of Medicine, Thomas Jefferson University, Philadelphia, PA (P.M.).
出版信息
Circ Res. 2014 Jan 3;114(1):12-4. doi: 10.1161/CIRCRESAHA.113.302748.
Abstract
摘要
相似文献
1
Cardiac calcium handling on trial: targeting the failing cardiomyocyte signalosome.
Circ Res. 2014 Jan 3;114(1):12-4. doi: 10.1161/CIRCRESAHA.113.302748.
2
MicroRNA therapy for the failing heart.
Circ Cardiovasc Genet. 2014 Jun;7(3):393-4. doi: 10.1161/CIRCGENETICS.114.000687.
3
Sarcoendoplasmic reticulum calcium transport ATPase 2a: a potential gene therapy target in heart failure.
Cardiol Rev. 2013 May-Jun;21(3):151-4. doi: 10.1097/CRD.0b013e3182749cdb.
4
Targeting sarcoplasmic reticulum calcium ATPase by gene therapy.
Hum Gene Ther. 2013 Nov;24(11):937-47. doi: 10.1089/hum.2013.2512.
5
Targeted sarcoplasmic reticulum Ca2+ ATPase 2a gene delivery to restore electrical stability in the failing heart.
Circulation. 2012 Oct 23;126(17):2095-104. doi: 10.1161/CIRCULATIONAHA.111.071480. Epub 2012 Sep 27.
6
Sarcoplasmic reticulum and calcium cycling targeting by gene therapy.
Gene Ther. 2012 Jun;19(6):596-9. doi: 10.1038/gt.2012.34. Epub 2012 May 17.
7
Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure.
Circulation. 2011 Jul 19;124(3):304-13. doi: 10.1161/CIRCULATIONAHA.111.022889. Epub 2011 Jun 27.
8
Heartening results: the CUPID gene therapy trial for heart failure.
Mol Ther. 2011 Jul;19(7):1181-2. doi: 10.1038/mt.2011.123.
9
Gene therapy for heart failure: an investigational treatment that is coming of age.
Rev Esp Cardiol. 2010 Feb;63(2):137-40. doi: 10.1016/s1885-5857(10)70030-x.
10
Cardiac gene therapy with SERCA2a: from bench to bedside.
J Mol Cell Cardiol. 2011 May;50(5):803-12. doi: 10.1016/j.yjmcc.2010.11.011. Epub 2010 Nov 18.
引用本文的文献
1
Gene Therapy for Cardiovascular Disease: Clinical Perspectives.
Yonsei Med J. 2024 Oct;65(10):557-571. doi: 10.3349/ymj.2024.0127.
2
Raf kinase inhibitor protein: lessons of a better way for β-adrenergic receptor activation in the heart.
J Physiol. 2017 Jun 15;595(12):4073-4087. doi: 10.1113/JP274064. Epub 2017 May 23.
3
Inhibition of cardiac CaMKII to cure heart failure: step by step towards translation?
Basic Res Cardiol. 2016 Nov;111(6):66. doi: 10.1007/s00395-016-0582-1. Epub 2016 Sep 28.
4
Gene therapy for cardiovascular disease: advances in vector development, targeting, and delivery for clinical translation.
Cardiovasc Res. 2015 Oct 1;108(1):4-20. doi: 10.1093/cvr/cvv205. Epub 2015 Aug 3.
本文引用的文献
1
Long-term effects of AAV1/SERCA2a gene transfer in patients with severe heart failure: analysis of recurrent cardiovascular events and mortality.
Circ Res. 2014 Jan 3;114(1):101-8. doi: 10.1161/CIRCRESAHA.113.302421. Epub 2013 Sep 24.
2
Heart failure gene therapy: the path to clinical practice.
Circ Res. 2013 Aug 30;113(6):792-809. doi: 10.1161/CIRCRESAHA.113.300269.
3
Immune responses to AAV vectors: overcoming barriers to successful gene therapy.
Blood. 2013 Jul 4;122(1):23-36. doi: 10.1182/blood-2013-01-306647. Epub 2013 Apr 17.
4
Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure.
Circulation. 2011 Jul 19;124(3):304-13. doi: 10.1161/CIRCULATIONAHA.111.022889. Epub 2011 Jun 27.
5
The complex and evolving story of T cell activation to AAV vector-encoded transgene products.
Mol Ther. 2011 Jan;19(1):16-27. doi: 10.1038/mt.2010.250. Epub 2010 Nov 30.
6
Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection.
Mol Ther. 2008 Jun;16(6):1073-80. doi: 10.1038/mt.2008.76. Epub 2008 Apr 15.
7
Reversal of cardiac dysfunction after long-term expression of SERCA2a by gene transfer in a pre-clinical model of heart failure.
J Am Coll Cardiol. 2008 Mar 18;51(11):1112-9. doi: 10.1016/j.jacc.2007.12.014.
8
Calcium cycling and signaling in cardiac myocytes.
Annu Rev Physiol. 2008;70:23-49. doi: 10.1146/annurev.physiol.70.113006.100455.
9
AAV2 vector harboring a liver-restricted promoter facilitates sustained expression of therapeutic levels of alpha-galactosidase A and the induction of immune tolerance in Fabry mice.
Mol Ther. 2004 Feb;9(2):231-40. doi: 10.1016/j.ymthe.2003.11.015.
10
Calcium signalling: dynamics, homeostasis and remodelling.
Nat Rev Mol Cell Biol. 2003 Jul;4(7):517-29. doi: 10.1038/nrm1155.
Zotero 插件